1. Biologic therapy for psoriasis: early response implies future success. (December 2013) Authors: Strober, B. Journal: British journal of dermatology Issue: Volume 169:Number 6(2013:Dec.) Page Start: 1178 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis. (1st December 2017) Authors: Papp, K.; Bachelez, H.; Costanzo, A.; Foley, P.; Gooderham, M.; Kaur, P.; Philipp, S.; Spelman, L.; Zhang, N.; Strober, B. Journal: British journal of dermatology Issue: Volume 177:Number 6(2017) Page Start: 1562 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis4. (1st December 2017) Authors: Papp, K.; Bachelez, H.; Costanzo, A.; Foley, P.; Gooderham, M.; Kaur, P.; Philipp, S.; Spelman, L.; Zhang, N.; Strober, B. Journal: British journal of dermatology Issue: Volume 177:Number 6(2017) Page Start: 1562 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Comprehensive long‐term safety of adalimumab from 18 clinical trials in adult patients with moderate‐to‐severe plaque psoriasis. (1st January 2019) Authors: Leonardi, C.; Papp, K.; Strober, B.; Thaçi, D.; Warren, R.B.; Tyring, S.; Arikan, D.; Karunaratne, M.; Valdecantos, W.C. Journal: British journal of dermatology Issue: Volume 180:Number 1(2019) Page Start: 76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Comprehensive long‐term safety of adalimumab from 18 clinical trials in adult patients with moderate‐to‐severe plaque psoriasis3. (10th October 2018) Authors: Leonardi, C.; Papp, K.; Strober, B.; Thaçi, D.; Warren, R.B.; Tyring, S.; Arikan, D.; Karunaratne, M.; Valdecantos, W.C. Journal: British journal of dermatology Issue: Volume 180:Number 1(2019) Page Start: 76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. (23rd August 2021) Authors: Reich, K.; Mrowietz, U.; Menter, A.; Griffiths, C.E.M.; Bagel, J.; Strober, B.; Nunez Gomez, N.; Shi, R.; Guerette, B.; Lebwohl, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 12(2021) Page Start: 2409 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. (31st October 2013) Authors: Strober, B.; Buonanno, M.; Clark, J.D.; Kawabata, T.; Tan, H.; Wolk, R.; Valdez, H.; Langley, R.G.; Harness, J.; Menter, A.; Papp, K. Journal: British journal of dermatology Issue: Volume 169:Number 5(2013:Nov.) Page Start: 992 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. (14th July 2021) Authors: Van Voorhees, A.S.; Stein Gold, L.; Lebwohl, M.; Strober, B.; Sofen, H.; Papp, K.; Bagel, J.; Zhang, Z.; Paris, M.; Wang, Y. Journal: British journal of dermatology Issue: Volume 185:Number 4(2021) Page Start: 840 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. (1st October 2021) Authors: Van Voorhees, A.S.; Stein Gold, L.; Lebwohl, M.; Strober, B.; Sofen, H.; Papp, K.; Bagel, J.; Zhang, Z.; Paris, M.; Wang, Y. Journal: British journal of dermatology Issue: Volume 185:Number 4(2021) Page Start: 840 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies. (3rd July 2020) Authors: Strober, B.; Menter, A.; Leonardi, C.; Gordon, K.; Lambert, J.; Puig, L.; Photowala, H.; Longcore, M.; Zhan, T.; Foley, P. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 12(2020) Page Start: 2830 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗